Thanks Chuckles, I appreciate your analysis as it corresponds to my own. I think the difference between Nader’s revenue projections and yours is the 1.6M dose projection. He is likely projecting significantly more doses than us assuming we get government assistance, and/or priority manufacturing. Regardless of the many assumptions, we are looking at a significant increase in stock price with an approval.